Interventional medical apparatus and preparation method thereof

Abstract

The present application discloses an interventional medical device and a preparation method thereof. The interventional medical device comprises: a stent body, the surface of the stent body is provided with a drug release structure, and the drug in the drug release structure inhibits adventitial fibroblasts Proliferative drugs and drugs that inhibit intima and / or smooth muscle cell proliferation. When the interventional medical device is implanted into the human body, the drug that inhibits the proliferation of adventitial fibroblasts carried on it can be slowly released into the blood vessel wall cells that are in contact with the stent body, thereby inhibiting adventitial fibroblasts. The proliferation of cells promotes the compensatory expansion of blood vessels. At the same time, the drugs carried on it that inhibit the proliferation of intima and / or smooth muscle cells can also inhibit the proliferation of vascular intimal to a certain extent. The two drugs work together to greatly reduce the The incidence of internal restenosis.

Description

technical field [0001] The present application relates to the technical field of medical devices, in particular to a drug-containing interventional medical device and a preparation method thereof. Background technique [0002] In recent years, in order to avoid the occurrence of in-stent restenosis after interventional treatment, the stent implanted in the human body is coated with a drug coating. Most of the currently used drug stents carry drugs that inhibit the proliferation of vascular intima or media, for example: rapamycin, paclitaxel and their derivatives, etc. When the stent carrying the above drugs is implanted in the human body, the stent will Continuously release drugs that inhibit the proliferation of the intima or media of the vessel to the vessel wall to reduce the incidence of in-stent restenosis. [0003] Studies have shown that the formation mechanism of intravascular restenosis is not only related to intima or media hyperplasia after vascular injury, but a...

AI Technical Summary

Problems solved by technology

[0004] Therefore, the existing drug stents that inhibit intima or media hyperplasia cannot minimize the incidence of in-stent restenosis

In addition, existing drugs that inhibit vascular intima or medial hyperplasia such as rapamycin, paclitaxel and their derivatives can inhibit the growth of endothelial cells, leading to the problem of delayed vascular endothelialization, and incomplete endothelialization of blood vessels may cause late thrombosis

Images